Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies

Atoyebi, Shakir Adeyinka ORCID: 0000-0002-1393-3753, Rajoli, Rajith KR ORCID: 0000-0002-6015-5712, Adejuyigbe, Ebunoluwa, Owen, Andrew ORCID: 0000-0002-9819-7651, Bolaji, Oluseye, Siccardi, Marco ORCID: 0000-0002-3539-7867 and Olagunju, Adeniyi ORCID: 0000-0002-6588-5749 (2019) Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide <i>versus</i> efavirenz as case studies. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 140. 105068-.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1016/j.ejps.2019.105068

Abstract

Maternofoetal physiologically-based pharmacokinetic models integrating multi-compartmental maternal and foetal units were developed using Simbiology® to estimate prenatal drug exposure. Processes governing drug disposition were described using differential equations with key system and drug-specific parameters. Transplacental drug transfer was modelled as bidirectional passive diffusion and benchmarked against those for thalidomide as a control. Model-predictions for pharmacokinetic parameters during pregnancy were within acceptable ranges for qualification (two-fold difference of clinically-observed values). Predicted foetal exposure to thalidomide was higher than efavirenz, with median (range) foetal-to-maternal plasma ratios of 4.55 (3.06-9.57) for 400 mg thalidomide versus 0.89 (0.73-1.05) for 400 mg efavirenz at third trimester. Model-predictions indicated foetal exposure consistently above 300% of maternal plasma concentration for thalidomide throughout pregnancy, while exposure to efavirenz increased from under 20% at second trimester to above 100% at third trimester. Further qualification of this approach as a tool in evaluating drug exposure and safety during pregnancy is warranted.

Item Type:	Article
Uncontrolled Keywords:	PBPK model, Efavirenz, Thalidomide, Pregnancy, Fetus
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	27 Sep 2021 07:15
Last Modified:	06 Oct 2023 17:06
DOI:	10.1016/j.ejps.2019.105068
Open Access URL:	https://www.sciencedirect.com/science/article/pii/...
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3138258